The invention provides hydrogel for treating
atopic dermatitis and application thereof, and relates to the technical field of
biomedicine, and the hydrogel comprises SA,
plasma water, L-G2 and / or FLA. Through in-vitro
cytotoxicity tests and antibacterial performance tests, preliminary evaluation is carried out on the hydrogel, it is proved that the hydrogel can inhibit
staphylococcus aureus and
escherichia coli, meanwhile, the hydrogel shows low
cytotoxicity, and the basic requirements of biomedical dressing are met. In animal experiments, by comparing
skin lesion conditions before and after AD mouse treatment, it is observed that the hydrogel can significantly improve back
skin lesion of a mouse and has a good anti-inflammatory effect. Pathohistological analysis shows that the hydrogel can reduce the thickness of epidermis, inhibit the increase of the TNF-alpha level induced by DNCB and promote
inflammation relief. Meanwhile, SA can provide a wet healing environment for
skin wounds and is beneficial to promoting wound repair. Therefore, the hydrogel provides a new strategy for AD treatment and management, and is expected to become a novel external
medicine for AD treatment.